Imagion Biosystems Ltd (ASX: IBX) Share Price and News

Ms Angus has worked as a senior executive within the biotechnology, medtech, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited, Cyclopharm Limited and Bionic Vision Technologies Limited as well as being a member of the Deakin University Council. She has built competitive and differentiated product portfolios, from investment in innovative research and product development to commercialisation and market entry. She is also a member of Disclosure Committee.

Mr Harsh is a co-founder and Chief Product Officer of Terapede Systems, a digital X-ray startup that focuses on developing an ultra-high resolution medical flat panel X-ray detector. Prior to co-founding Terapede Systems in 2015, Mr. Harsh had a 36-year long career with General Electric, including serving as Global Technology Leader Imaging Technologies at the GE Global Research Center and culminating with him serving as Vice President and Chief Technology of GE Healthcare. He had previously served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is member of Risk Committee.

Mr Asten has over 30 years of experience in the medical diagnostics and life sciences industry. Much of this time has been in international business development, strategic planning, and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of several innovative technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He is also a member of Risk Committee.

Mr Ludvigson is currently a director (was formerly President and CEO) af Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including Biogen (formerly IDEC Pharmaceuticals), Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new product efforts from concept to market launch. David has conducted many strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He is also a member of Risk and Disclosure Committee.

Mr Proulx has been CEO and President of Imagion Biosystems since February 2015. Previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries. Some of Robert's other relevant experience includes Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.

Ms Naumoska is an Australian-qualified corporate lawyer with experience in legal and regulatory issues pertaining to medical imaging technology. Jovanka is currently a nonexecutive director of Security Matters Limited and serves Australian scientific development organisations in an expert capacity on matters relating to corporate law, business operations, intellectual property development and regulatory compliance. She is also a member of Disclosure Committee.

Dr Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics, Inc. before its trade sale to iBio, Inc. (NYSEA: IBIO) in September 2022. Prior to launching Rubric, Dr Bright was Chief Business Officer for molecular diagnostics innovator Health Tell, Inc., driving its trade sale to iCarbonX, concomitant with RubrYcs launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics, Inc. and consoling Chief Business Officer for synthetic biology innovator musebio, Inc. (currently Incripta, Inc.)Dr Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016. With Merieux, Dr Bright led investments and Board representation for Imaginab, Inc., Kalila Medical, Inc. its acquisition by Abbo (NYSE: ABT), and Twist Bioscience before its IPO (NASDAQ: TWST). Dr Brights startup experience began as he built and led QuantaLife, Inc.s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLifes acquisition by Bio-Rad Laboratories, Inc. (NYSE: BIO). Previously, Dr Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic (NYSE: MDT).

-

-

-